FTSE 100 Index Ends 1.82% Lower at 7820.36 — Data Talk
The FTSE 100 Index is down 145.17 points or 1.82% today to 7820.36
--Largest one day point and percentage decline since Thursday, July 6, 2023
--Down for two consecutive trading days
--Down 175.22 points or 2.19% over the last two trading days
--Largest two day point and percentage decline since Friday, Oct. 20, 2023
--Down three of the past four trading days
--Off 2.42% from its record close of 8014.31 hit Monday, Feb. 20, 2023
--Up 23.39% since the pre-Brexit vote level of 6338.10 hit Thursday, June 23, 2016
--Lowest closing value since Wednesday, March 20, 2024
--Off 2.19% from its 52-week high of 7995.58 hit Friday, April 12, 2024
--Up 7.76% from its 52-week low of 7256.94 hit Friday, July 7, 2023
--Down 1.13% from 52 weeks ago
--Off 2.19% from its 2024 closing high of 7995.58 hit Friday, April 12, 2024
--Up 5.02% from its 2024 closing low of 7446.29 hit Wednesday, Jan. 17, 2024
--Month-to-date it is down 1.66%
--Year-to-date it is up 87.12 points or 1.13%
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 16, 2024 12:33 ET (16:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year